Results 91 to 100 of about 12,232 (185)

PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report

Frontiers in Cardiovascular Medicine
BackgroundApproximately 3.8 million patients in China suffer from familial hypercholesterolemia (FH). Statins and PCSK9 inhibitors are recommended by guidelines as therapeutic agents.
Yuan Li, Huiyan Jiang, Yajuan Xiong, Simin Yan, Xin Chen   +4 more
doaj   +1 more source

PCSK9 Inhibitors

Journal of the American College of Cardiology, 2017
Mark A. Hlatky, Dhruv S. Kazi
openaire   +2 more sources

PCSK9 inhibition: from effectiveness to cost-effectiveness

Frontiers in Cardiovascular Medicine
Dyslipidaemia is a complex disorder characterised by abnormal lipid levels in the blood, including cholesterol and triglycerides, and plays an important role in the development of atherosclerotic cardiovascular disease.
Iveta Mercep, Iveta Mercep, Dominik Strikic, Pero Hrabac, Ivan Pecin, Željko Reiner, Željko Reiner   +6 more
doaj   +1 more source

Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders

Vascular Health and Risk Management, 2016
Sanjiv Gupta Department of Interventional Cardiology, Santokba Durlabhji Memorial Hospital Cum Medical Research Institute, Jaipur, India Abstract: The aim of this manuscript is to review available data to evaluate the present status of proprotein ...
Gupta S
doaj  

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome

Инновационная медицина Кубани
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in the regulation of blood cholesterol levels by binding to low-density lipoprotein receptors and promoting their degradation. Pivotal studies have shown that PCSK9 inhibition by
A. M. Namitokov, V. K. Zafiraki, K. V. Karabakhtsieva   +2 more
doaj   +1 more source

PCSK9 inhibitors in the current management of atherosclerosis

Archivos de Cardiología de México, 2017
The history of proprotein convertase subtilisin/kexin type 9 (PCSK9) in medical science is fascinating and the evolution of knowledge of its function has resulted in new medications of major importance for the cardiovascular (CV) patient. PCSK9 functions as a negative control or feedback for the cell surface receptors for low-density lipoprotein ...
openaire   +2 more sources

PCSK9 in peripheral arterial disease: Mechanisms and therapeutic perspectives

Science Progress
This narrative review comprehensively examines the multifaceted roles of proprotein convertase subtilisin/kexin type 9 (PCSK9) in peripheral arterial disease (PAD).
Yue Gao, Jing Zhang, Nan Jiang, Lijuan Wang, Tingbing Cao, Yangli Xie, Hongbo He, Li Li   +7 more
doaj   +1 more source

Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Background Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to
Guoying Kao, Chuan Chen, Ying Zhang, Yi Xu, Gang Xu   +4 more
doaj   +1 more source

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab

Vascular Health and Risk Management, 2016
Dirk J Blom,1 Ricardo Dent,2 Rita C Castro,2 Peter P Toth3,4 1Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa; 2Amgen, Inc., Thousand Oaks, CA, 3Ciccarone Center for the Prevention of Cardiovascular ...
Blom DJ, Dent R, Castro RC, Toth PP
doaj  

Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis

International Journal for Equity in Health
Background PCSK9 inhibitors are a novel class of lipid-lowering drugs that have demonstrated favorable efficacy and safety. Evolocumab and alirocumab have been added to China’s National Reimbursement Drug List through the National Drug Price Negotiation (
Lingli Zhang, Xiaoye Wang, Hongting Yao, Baolong Ding, Xingyuan Gao, Xin Li   +5 more
doaj   +1 more source